Status:
COMPLETED
Implementation of FEES in Spinal Muscle Atrophy
Lead Sponsor:
University of Giessen
Conditions:
Spinal Muscular Atrophy
Eligibility:
All Genders
Phase:
NA
Brief Summary
The major aim of this project is to assess comprehensively frequency and extent of dysphagia and bulbar dysfunction in SMA1, 2, and 3 patients by applying FEES and validated dysphagia scores. Further ...
Detailed Description
Spinal muscular atrophy (SMA) is a progressive autosomal recessive neuromuscular disease characterized by premature degeneration of the 2nd motor neuron and a broad phenotype. SMA results from biallel...
Eligibility Criteria
Inclusion
- All patients with genetically determined 5q-linked SMA followed at the neuromuscular center Gießen
- \- Informed and written consent signed by the patient or a legal guardian
Exclusion
- Physical illness that, according to its type and severity, could interfere with the planned assessments, could have an influence on the parameters to be investigated or could endanger the patient or test person during the course of the investigation.
- Pregnancy or lactation and a positive pregnancy test
- Acute suicidal tendency or external danger
- Poor general condition
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT04773470
Start Date
February 1 2022
End Date
September 30 2024
Last Update
December 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Giessen and Marburg, Campus Giessen
Giessen, Hesse, Germany, 35392